不同吸入激素与长效支气管扩张剂组合对重症慢阻肺气道微生物组的影响:MUSIC随机试验
MUSIC多中心随机对照试验纳入重症慢阻肺患者,洗脱4周后随机接受布地奈德/福莫特罗400/12µg、氟替卡松/沙美特罗500/50µg或250/50µg、阿地溴铵/福莫特罗340/12µg治疗3个月。主要终点为口咽拭子细菌负荷,BF400与FS500无显著差异;但FS500组第3个月痰细菌负荷较BF400显著增加,FS250未见此差异。ICS洗脱耐受性差,61例随机前退出。
要点
- 重症慢阻肺ICS洗脱耐受性差,122例中61例随机前退出,45例发生急性加重。
- FS500较BF400第3个月痰细菌负荷显著增加,但口咽细菌负荷主要终点无差异。
- FS250未出现痰细菌负荷增加,提示不同ICS制剂对气道微生物组影响可能不同。
核心结论
- 氟替卡松/沙美特罗500/50µg增加痰细菌负荷但不增加上气道细菌负荷。
- 重症慢阻肺患者ICS洗脱耐受性差。
研究设计与样本
- 多中心随机对照试验,纳入FEV1<50%预计值和/或每年≥2次急性加重的慢阻肺患者。
- 4周ICS洗脱后随机分配至BF400、FS500、FS250或阿地溴铵/福莫特罗340/12µg,每日两次,随访3个月。
- 122例开始洗脱,61例随机,每月采集诱导痰、口咽和鼻咽拭子行细菌负荷和16S rRNA测序。
主要发现
- 主要终点BF400与FS500口咽拭子细菌负荷无统计学显著差异。
- 第3个月FS500组痰细菌负荷较BF400组显著增加。
- FS250组未观察到痰细菌负荷增加。
- 微生物组α多样性随时间无显著差异。
- 不良事件组间相似。
关键数值与推荐
- 主要终点:口咽拭子细菌负荷(BF400 vs FS500)。
- 关键次要终点:痰细菌负荷。
- ICS洗脱期122例中61例退出,45例发生急性加重。
临床怎么用
- 重症慢阻肺患者撤除ICS需密切监测急性加重风险。
- 选择含氟替卡松500/50µg方案时需关注痰细菌负荷增加的可能。
局限性
- ICS洗脱期退出率高,仅61例随机,样本量有限。
- 随访时间仅3个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The microbiome is associated with exacerbation risk, quality of life and mortality in COPD. Inhaled corticosteroid (ICS) treatment has been reported to alter the microbiome through modulating host defence. How ICS alters the microbiome and whether effects are equal between different ICS preparations is debated. The aim of the MUSIC trial was to investigate whether commonly used ICS therapies have different effects on the airway microbiome in COPD. METHODS: This was a multicentre randomised controlled trial. After a 4-week washout period during which they withdrew from ICS, patients with COPD (forced expiratory volume in 1 s <50% predicted at baseline and/or a history of two or more exacerbations per year) were randomised to one of four treatments (budesonide/formoterol 400/12 µg (BF400), fluticasone/salmeterol 500/50 µg (FS500), fluticasone/salmeterol 250/50 µg (FS250) or aclidinium/formoterol 340/12 µg, twice daily). Patients were followed-up for 3 months with monthly induced sputum, oropharyngeal and nasopharyngeal swabs for bacterial load and 16S rRNA sequencing to characterise the microbiome. Inflammatory markers were measured in sputum and blood. The primary outcome was bacterial load in oropharyngeal swabs comparing BF400 versus FS500, with sputum bacterial load the key secondary end-point. RESULTS: 122 participants started the washout period. ICS withdrawal was poorly tolerated; 61 participants withdrew before randomisation with 45 experiencing an exacerbation. 61 patients were randomised. No statistically significant differences were observed for the primary comparison of BF400 versus FS500 in oropharyngeal bacterial load. There was, however, a significant increase in sputum bacterial load with FS500 compared to BF400 by month 3. This difference was not seen with FS250. No significant differences in microbiome α-diversity were observed over time. Adverse events were similar between the groups. CONCLUSION: FS500 increased sputum but not upper airway bacterial loads. ICS withdrawal was poorly tolerated in severe COPD.
引用
- Richardson, Alferes De Lima Headley, Clarke, et al. The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC). Eur Respir J. 2025. PMID: 40841147. doi:10.1183/13993003.00287-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。